Kiromic BioPharma : Corporate Presentation

BioPharma

Revolutionizing CAR T-Cell Therapy

March 2024

OTCQB: KRBP Kiromic.com

Forward Looking Statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. Kiromic makes such forward-looking statements pursuant to the safe harbor provisions of the United States Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as: "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding: Kiromic's current and anticipated IND applications including statements regarding the scope of and timing for submission of an IND application; the Deltacel™ product platform; the sponsored research agreement and the data that will be generated as a result of such collaboration; the timing for submitting and activating Kiromic's IND applications; the benefits of utilizing non-genetically engineered Gamma Delta T cells as our first in-human study; Kiromic's ability to achieve its objectives; and the timing for the initiation and successful completion of Kiromic's clinical trials of its product candidates. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in our Annual Report on Form 10-K for the year ended December 31, 2022, and as detailed from time to time in our SEC filings. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward- looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Such forward-looking statements relate only to events as of the date of this press release. We undertake no obligation to update any forward-looking statements except to the extent required by law.

PAGE

| 2

PAGE

| 3

Contents

The Kiromic Difference and Market Opportunity

Diamond AITM (Artificial Intelligence)

Gamma Delta T-cell (GDT) Therapy:

Mechanism of Action (MOA), Product Pipeline, cGMP Manufacturing

Current Status and Path Forward

The Kiromic Difference

PAGE

| 4

Kiromic BioPharma

is an allogeneic Gamma

Delta T-cell therapy

company featuring unique, proprietary, end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors

1	2		2		3
Diamond AITM	Gamma Delta	Allogeneic,
Neural			CAR-T Cell	Off-the-shelf
Network			Therapy		Cellular Therapy
			Platform		not ill cancer patients,
					Cells from healthy donors,
	4				for maximum efficacy
4				5
Solid
Malignancies	In-House
cGMP
	(~90% of all
	Manufacturing
	cancers1)

1American Cancer Society, Cancer Facts & Figures,

2022..https://www.cancer.org/research/cancer-facts-statistics.html.

Strategic Competitive Landscape

8 Known Companies in the Gamma Delta T Cell Therapy space. No Known Competitors with AI-drivenTechnology Combined with a Gamma Delta CAR-TDelivery Platform.

PAGE

| 5

AI-DRIVEN

CAR-GDT

Solid Malignancy Market Opportunity

Global CAR T-Cell
Therapy Market	90%
by 20271 (USD)
$33+
Billion	of Cancers Are
Solid Malignancies2

1. Global CAR T-Cell Therapy Market, By Product Type, By Tumor Type, By Indication, By Treatment Type, By Targeted Antigen, By End User, By Region, Competition, Forecast and Opportunities, 2017-2027 (ReportLinker)
2. American Cancer Society, Cancer Facts & Figures, 2022..https://www.cancer.org/research/cancer-facts- statistics.html

PAGE

| 6

Competitive Difference

Allogeneic Gamma Delta Based T-Cell Therapies

PAGE

| 7

Superior

specificity for multiple solid tumors

Superior

Efficacy from

γδT cells

• Potential broad treatment for solid malignancies that express Kiromic-developedbiomarkers such as Iso- mesothelin.
• Solid tumors represent approx. 90% of new cancer diagnoses but finding specific targets to treat them has been challenging.
• Kiromic tackles the issue by identifying new cancer specific targets.
• Strong efficacy in pre-Clinical animal models.
• In solid tumors, the benefit of infiltrating conventional T cells may vary.
• In contrast, GDT cells are the infiltrating immune cells most likely to be associated with positive outcomes, as shown in an analysis of 18,000 tumors from 39 indications1

Vertical

Integration

Lower Costs/

Greater Access2

• In-house cGMP manufacturing
• In-houseQC/EM lab
• In-house product and process development (R&D and MSAT)

1.Outpatient treatment means reduced hospitalization and other treatment related costs.

2. Lower projected cost

increases patient and health care professional access to these therapies, and potentially provides important quality-of-life benefits for patients as well.

1. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015 Aug;21(8):938-945.
2. Maziarz RT. CAR T-cell therapy total cost can exceed $1.5M per treatment. Cell Therapy Next; May 29, 2019.

PAGE

| 8

Contents

The Kiromic Difference and Market Opportunity

Diamond AITM (Artificial Intelligence)

Gamma Delta T-cell (GDT) Therapy:

Mechanism of Action (MOA), Product Pipeline, cGMP Manufacturing

Current Status and Path Forward

Artificial Intelligence and Bioinformatic Analytic Discovery & Development Platform

Algorithms and Large-Scale Genomics Analysis for Target Prediction

PAGE

| 9

Discovery

Development

Manufacturing

Clinical Trials

A.I. integrated with each stage of the Kiromic therapy production lifecycle Discovering New Multi-tumor Targets

Identifying Optimal Donors and Patients to Maximize the Therapy Success

The Kiromic Difference - Diamond AITM Target Discovery Platform

Diamond AITM target discovery platform powers innovation and significantly reduces development time and cost.

PAGE

| 10

• Diamond AI drives discovery by sifting through billions of data points to identify cancer specific immunotherapy targets, donors with the best GDT cell yields, and patients who will most likely benefit from our therapies.

Large Cancer Genomics	Diamond AITM
Studies	Data Mining Tools

2 Diamond AI prediction and

validation platform reduce
development costs by seeking	3 Laboratory studies are then
to eliminate targets, donors,
and patients that will	performed to confirm the validity
ultimately fail laboratory	of the AI selections.
analysis.

	•	Cancer / Normal
		Differences
Large Normal Tissue	•	Cell Surface Proteins
Genomics Studies	•	Unique Targetable
		Peptides
	•	Optimal Donor and
		Patient Selection

Protein Structures, Gene

Models, Gene Metadata

Target	Target	Therapy Candidates
Donor &	Validation
Patient	(Algorithm and
Selection	wet lab Validation)

• Diamond Donor AI uses demographics, cytometry, and sequence data to identify the best GDT cell donors -
  reducing manufacturing cost and potentially improving potency. Diamond data mining can guide selecting patients likely to benefit from Kiromic's therapies.

Clinical Trials

(Phase I)

*

Diamond Clinical AI models can continually improve the AI model to maximize efficacy.

• In Development